Inflation: Shoppers, Get Ready to Pay More for Coffee, Beer, Bread and Snacks
Bloomberg · 2d ago
Unlocking Unilever's Value Could Be the Next Big Thing for Activist Hedge Funds
Bloomberg · 07/16 05:00
Supreme Court Backs Nestle, Cargill on Child-Slavery Suit
Bloomberg · 06/17 20:02
Nestle Eyes Nature’s Bounty Acquisition to Boost Vitamin Sales
After ditching big chunks of its chocolate and ice cream businesses, Nestle SA Chief Executive Officer Mark Schneider is embracing healthier living by bulking up on vitamins and supplements.
Bloomberg · 04/26 08:22
Contactless Coffee
Nestle wants to get in on the back-to-office push with new contactless Nespresso machines (Source: Quicktake)
Bloomberg · 04/05 21:59
Wall Street Breakfast: Anticipation Builds For iPhone 12
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Anticipation builds for iPhone 12Wedbush is calling today's Apple (AAPL) iPhone event a "once in a decade" potential launch, and the stock is responding accordingly. Shares are up 2% premarket, following a 6.4% advance on Monday, amid expectations that it will be the first iPhone with full 5G capacity and cheaper than last year's devices. Analyst Daniel Ives predicts four iPhone models: 5.4-inch OLED display (starting price: $699); 6.1-inch OLED display ($799), 6.1-inch iPhone Pro OLED
Seekingalpha · 10/13/2020 11:04
Aimmune shareholders accept $2 billion Nestle tender offer
Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic. Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date.
Reuters · 10/13/2020 06:39
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. ((SPN)), a Nestle (NSRGY) subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics' (AIMT) common stock for
Seekingalpha · 10/13/2020 06:16
Are Insiders Buying Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Stock?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Simply Wall St. · 10/06/2020 12:20
Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).Nestle has commenced a tender offer to purchase shares of AIMT at $34.50 per share and it is trying to take advantage of the unwarranted selloff.Given recent developments with AIMT and its competitor, DBV Technologies, I believe this offer price is woefully inadequate.
Seekingalpha · 09/21/2020 10:23
Nestle Acquiring Aimmune, And Other News: The Good, Bad And Ugly Of Biopharma
Aimmune to be acquired by Nestle for $2.6 billion.Mallinckrodt receives a CRL for Terlipressin.Cassava reports positive final data for Alzheimer’s treatment.
Seekingalpha · 09/21/2020 04:18
Nestlé Launches $2.6B Tender Offer For Aimmune Therapeutics
Nestlé S.A. has announced that its wholly-owned subsidiary, SPN Merger Sub, Inc, has now made a cash tender offer to buy all outstanding shares of food-allergy specialist Aimmune Therapeutics (AIMT) for $34.50 per share in cash, without interest and subject to any withholding taxes.This represents a
SmarterAnalyst · 09/14/2020 09:48
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) ("Aimmune
PR Newswire · 09/14/2020 05:15
AstraZeneca's Farxiga Data, And Other News: The Good, Bad And Ugly Of Biopharma
AstraZeneca reports positive data for Phase III Farxiga trial. Aimmune Therapeutics to be acquired by Nestle.
Seeking Alpha - Article · 09/02/2020 09:36
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Akcea Therapeutics, Inc. (Nasdaq -AKCA), Aimmune Therapeutics, Inc. (Nasdaq -AIMT), Rosetta Stone Inc. (NYSE - RST)
BALA CYNWYD, PA / ACCESSWIRE / September 1, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.
ACCESSWIRE · 09/02/2020 00:10
MERGER ALERT AIMT, PRNB, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 1, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
ACCESSWIRE · 09/01/2020 18:50
Rigrodsky & Long, P.A. Announces Investigation of Aimmune Therapeutics, Inc. Buyout
WILMINGTON, DE / ACCESSWIRE / September 1, 2020 / Rigrodsky & Long, P.
ACCESSWIRE · 09/01/2020 16:30
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
Zacks · 09/01/2020 15:31
Company News for Sep1, 2020
Companies In The News Are: CTLT, TSLA, AIMT, AMZN.
Zacks · 09/01/2020 14:12
Credit Suisse Maintains Neutral on Aimmune Therapeutics, Raises Price Target to $34.5
Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and raises the price target from $14 to $34.5.
Benzinga · 09/01/2020 12:32
Webull provides a variety of real-time AIMT stock news. You can receive the latest news about Aimmune through multiple platforms. This information may help you make smarter investment decisions.
About AIMT
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.